Articles

The top priority for employers regarding their employees’ cancer care coverage is ensuring access to state-of-the-art care. Learn how employers are trying to close the gap between “typical” and “optimal” care. Read More ›

Telling the story of the Oncology Care Model and its performance over the past 5 years through some of the best-performing practices. Read More ›

Cancer care is complex and expensive, making a one-size-fits-all approach to drug benefit designs and coverages an unfavorable solution for patients with cancer. In this session, panelists discuss drug benefit reforms and the intended and unintended consequences of the recommended provisions. Read More ›

With more than 1.8 million diagnoses of cancer per year in the United States, identifying malignancies at the earliest stage is priority among physicians. In this session, experts discuss the future of early-stage cancer diagnosis and how to improve cancer screenings. Read More ›

Oncology nurse and patient navigators are playing an ever-increasing role in supporting patients with cancer and their caregivers. In this session, experts discuss the standardized measures and processes used by oncology nurse and patient navigators. Read More ›

In this session, experts discuss the challenges faced at the beginning of the COVID-19 pandemic, how they worked to overcome them, and what lessons they will take with them into the future. Read More ›

Specialized oncology pharmacy programs are playing an ever-increasing role in the complex delivery of care. In this session, panelists discuss the obstacles and successes of specialized oncology pharmacy programs. Read More ›

In this session, a panel of experts share the Wall Street perspective on the opportunities and challenges ahead for cancer drug developers and healthcare providers. Read More ›

Healthcare continues to adapt to the economic impact of the COVID-19 pandemic. In this session, industry experts discuss the underlying trends and economic realities of cancer care in the United States and global markets. Read More ›

The increased complexity of new oncology drugs and the accelerated rate of their approval has led to greater demands from stakeholders across the cancer care continuum. In this session, panelists discuss oncology drug supply chain channels and how they are incorporated in the move to value-based care. Read More ›